The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
301-666 Sherbrooke Street West
Montreal, QC H3A 1E7 Canada
The Canadian Hemophilia Society (CHS) is a registered charity dedicated to improving the quality of life for all persons with hemophilia and other inherited bleeding disorders. CHS was established in 1953. Its goals and objectives are to assure that all persons with hemophilia have ready access to the highest possible level of care; assure that the hemophilia community and public are kept informed; that research will continue to improve care and seek a cure for hemophilia, and to assist persons with hemophilia living in third world countries to ensure that they receive appropriate care. CHS works in collaboration with the Network of Rare Blood Disorder Organizations (NRBDO), a coalition of national patient groups, formed to share the best practices in health care delivery for people with hemophilia and other rare blood disorders. Hemophilia is a rare inherited blood clotting (coagulation) disorder caused by inactive or deficient blood proteins (usually factor VIII). Factor VIII is one of several proteins that enable the blood to clot. Hemophilia may be classified as mild, moderate, or severe. The level of severity is determined by the percentage of active clotting factor in the blood (normal percentage ranges from 50 to 150 percent).
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.